Cargando…

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)

Clostridioides difficile infection (CDI) is a major cause of nosocomial diarrhea that is deemed a global health threat. C. difficile strain BI/NAP1/027 has contributed to the increase in the mortality, severity of CDI outbreaks and recurrence rates (rCDI). Updated CDI treatment guidelines suggest va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kullar, Ravina, Tran, Mai-Chi N, Goldstein, Ellie J C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553590/ https://www.ncbi.nlm.nih.gov/pubmed/33116952 http://dx.doi.org/10.2147/JEP.S242959

Ejemplares similares

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention of Clostridioides difficile Infections
por: McFarland, Lynne V., et al.
Publicado: (2023)

Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in Clostridium difficile Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab
por: Shaw, Peter, et al.
Publicado: (2017)

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials
por: Sims, Matthew, et al.
Publicado: (2021)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
por: Bobilev, Dmitri, et al.
Publicado: (2019)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022)

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Extraintestinal Clostridioides difficile Infection (CDI): A Recurrent Battle with Resilient Abdominal Wall Abscess
por: Chinnappan, Justine, et al.
Publicado: (2023)

1211. Response to Fecal Microbiota Transplant (FMT) in Refractory Clostridioides difficile Infection (CDI) is Modest Compared to Recurrent CDI in Hospitalized Patients
por: Shin, Jae Hyun, et al.
Publicado: (2020)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

COVID-19 and Clostridioides difficile infection (CDI): Possible implications for elderly patients
por: Spigaglia, Patrizia
Publicado: (2020)

2’-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection
por: Wiese, Maria, et al.
Publicado: (2022)

Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?
por: McFarland, Lynne V., et al.
Publicado: (2022)

Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales
por: Tydeman, Florence, et al.
Publicado: (2021)

Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)
por: Manthey, Carolin F., et al.
Publicado: (2019)

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
por: Viprey, Virginie F, et al.
Publicado: (2022)

1966. Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived From a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent Clostridium difficile Infections (rCDI)
por: Blount, Ken, et al.
Publicado: (2018)

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI
por: Dicks, Leon M. T.
Publicado: (2023)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

710. Burden of Clostridioides difficile Infection (CDI) in Flint, Michigan (MI): Association of Race and Gender with Mortality
por: Younas, Mariam, et al.
Publicado: (2023)

RCDI/eRCDI: a web-server to estimate codon usage deoptimization
por: Puigbò, Pere, et al.
Publicado: (2010)

1930. Quality of Life among Patients with Community-onset Clostridioides difficile Infection (CDI) without Subsequent Hospitalization
por: Schmidt, Mark A, et al.
Publicado: (2023)

135. Impact of Clostridioides difficile Toxin Confirmation on Subsequent C. difficile Treatment in a Rural Health System (IT-CDI)
por: Crawford, Jacquelyn, et al.
Publicado: (2023)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI?
por: Popa, Daniel, et al.
Publicado: (2021)

Reductions in inpatient fluoroquinolone use and postdischarge Clostridioides difficile infection (CDI) from a systemwide antimicrobial stewardship intervention
por: Jones, K. Ashley, et al.
Publicado: (2021)

395. Impact of Racial Disparities on Clostridioides difficile Infection (CDI) Outcomes at a Southern California Academic Teaching Hospital
por: Zhou, Anna Y, et al.
Publicado: (2022)

1929. Evaluating Disparities in Recurrent Clostridioides difficile Infection (CDI) and Fecal Microbiota Transplant (FMT) Treatment using Geospatial and Social Vulnerability Analytic Tools
por: Little, Keighly, et al.
Publicado: (2023)

394. Impact of Misdiagnosis of Clostridioides difficile Infection (CDI) by Standard-of-care Specimen Collection and Testing on Estimates of Hospitalized CDI Incidence Among Adults in Louisville, Kentucky, 2019-2020
por: Ramirez, Julio A, et al.
Publicado: (2022)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

1498. Assess Risk Factors, Mortality, and Healthcare Utilization Associated with Clostridioides difficile Infection (CDI) in 4 Latin American Countries
por: Yu, Holly, et al.
Publicado: (2019)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sbklfkkffel769vn1vqta7lb3q